NVCT

Announcements

Nothing here yet

Daily updates

Nothing here yet

FDA designations

Nothing here yet

News

• Nuvectis reports Breakthrough Therapy Designation in China for NXP200 in BRAF V600-mutant recurrent or progressive high-grade gliomaSep 24, 2026
• Nuvectis expanded its portfolio through a licensing agreement with Haisco for ex-China rights to two clinical-stage compoundsJun 22, 2026
• Nuvectis initiates Phase 1b study of NXP900 with osimertinib in NSCLC patientsDec 17, 2025
• Nuvectis Pharma announces initiation of Phase 1b program for NXP900Aug 13, 2025
• Nuvectis Pharma provides final clinical data update from NXP800 Phase 1b study in ovarian cancer and reports completion of NXP900 Phase 1a dose escalation studyJul 31, 2025